Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below.
A question about retatrutide discussion that I think has a definite answer, unlike most of what I ask here.
I have the reasoning below and I am fairly confident about the direction. I am not confident about the size, and the size is what the decision turns on.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
That holds for the case as described. Change the assumptions and it may not.
Everything in post #5 holds. The case it does not cover is the one I have.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
That has held every time I have looked, which is not the same as always.
That is a cleaner way of putting what I was circling around.
Taking post #10 at face value and following it one step further.
Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.
Read the full topic (13 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. I would like to disagree…
|
+43 | 47 | 19k | 2d |
|
About the Retatrutide category
Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
4 | 12k | 2y | |
|
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…
|
+114 | 120 | 1.4k | 10mo |
|
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…
|
+51 | 56 | 700 | 22mo |
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
|
+149 | 159 | 30k | 15mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
|
+71 | 79 | 906 | 3mo |
|
About the N-of-1 designs category
Designing a personal experiment that could actually change your mind, including washouts and blinding. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 22k | 14h | |
|
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…
|
+48 | 53 | 31k | 13mo |
|
Amylin and gastric emptying: overlapping mechanisms with incretins
On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Posting a small dataset on amylin and gastric emptying. It is mine, it…
|
2 | 50k | 17mo | |
|
Revisiting: How this community labels and discusses unrefereed work
Revisiting: How this community labels and discusses unrefereed work Writing it up because I had to work it out twice and would rather nobody else did. Reading an unrefereed manuscript properly, and asking…
|
+31 | 35 | 7k | 1d |